Budesonide aerosolised formulation - AstraZeneca/SkyePharma

Drug Profile

Budesonide aerosolised formulation - AstraZeneca/SkyePharma

Alternative Names: Budesonide pMDI - AstraZeneca; Pulmicort HFA; Pulmicort HFA-MDI; Pulmicort pMDI

Latest Information Update: 08 Mar 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca; SkyePharma PLC
  • Developer AstraZeneca
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Market Withdrawal Asthma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 08 Mar 2011 Production discontinued for Asthma in Austria (Inhalation)
  • 08 Mar 2011 Production discontinued for Asthma in Denmark (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top